Data From Incyte’s Oncology Portfolio Accepted for Presentation at the 2021 EHA Virtual Congress
12.5.2021 23:18:00 EEST | Business Wire | Press release
Incyte (Nasdaq:INCY) today announced that multiple abstracts highlighting data from its oncology portfolio will be presented during the upcoming European Hematology Association (EHA) 2021 Virtual Congress, held virtually from June 9-17, 2021.
“We are pleased that data highlighting the strength of Incyte’s oncology portfolio and partner-sponsored programs will be presented at this year’s EHA Virtual Congress,” said Peter Langmuir, M.D., Group Vice President, Oncology Targeted Therapeutics, Incyte. “In particular, data being presented at the congress – including the first presentation of data from our Phase 2 study of parsaclisib, our PI3kδ inhibitor, in autoimmune hemolytic anemia; an oral presentation on real-world data for ruxolitinib, our JAK1/JAK2 inhibitor; and an ePoster from our Phase 2 combination study of ruxolitinib and parsaclisib in patients with myelofibrosis – reinforce our commitment to finding solutions for patients with significant unmet medical needs.”
Key abstracts accepted by EHA include:
Oral Presentations
Ponatinib
OPTIC Primary Analysis: A Dose-Optimization Study of 3 Starting Doses of Ponatinib (PON)1 (Abstract #S153. Session: Response, Resistance and Treatment-Free Remission in CML.)
Ruxolitinib
Efficacy and Safety of Ruxolitinib in Patients with Steroid-Refractory Acute Graft-Vs-Host Disease After Crossover in the Phase 3 REACH2 Study2 (Abstract #S236. Session: Stem cell transplantation – GvHD.)
Impact of Ruxolitinib on Survival of Patients with Myelofibrosis in Real World – Update of ERNEST (European Registry for Myeloproliferative Neoplasms) Study2 (Abstract #S158. Session: Population based studies in myeloid disorders.)
ePosters
Parsaclisib
Efficacy and Safety Results from an Open-Label Phase 2 Study of Parsaclisib for the Treatment of Autoimmune Hemolytic Anemia (AIHA) (Abstract #EP685. Session: Enzymopathies, Membranopathies and Other Anemias.)
Pharmacologic Inhibition of PI3kδ Reduces Autoantibody Formation and is Efficacious in a Preclinical Model of Autoimmune Hemolytic Anemia (Abstract #EP693. Session: Enzymopathies, Membranopathies and Other Anemias.)
FACIT-Fatigue Subscale Outcomes from an Ongoing Phase 2, Open-Label Study of the Phosphatidylinositol 3-Kinase Delta (PI3Kδ) Inhibitor Parsaclisib in Patients with Autoimmune Hemolytic Anemia (AIHA) (Abstract #EP706. Session: Enzymopathies, Membranopathies and Other Anemias.)
Ponatinib
French Real-Life Observational Study “TOPASE” Evaluating Safety and Efficacy of Ponatinib Confirms Induction of Deep Molecular Responses in 110 Resistant or Intolerant CML Patients (Abstract #EP679. Session: Chronic Myeloid Leukemia – Clinical.)
Ruxolitinib
An Epidemiological Study of the Cardiovascular Health and Thrombotic Risk Profiles of Patients with Myeloproliferative Neoplasms in Primary Care Across the United Kingdom2 (Abstract #EP1090. Session: Myeloproliferative Neoplasms – Clinical.)
Impact of Bone Marrow Fibrosis Grade on Response and Outcome in Patients with Primary Myelofibrosis Treated with Ruxolitinib: A Post-Hoc Analysis of the JUMP Study2 (Abstract #EP1092. Session: Myeloproliferative Neoplasms – Clinical.)
Healthcare Resource Utilization in Patients with Myeloproliferative Neoplasms: A Nationwide Matched Cohort Study2 (Abstract #EP1107. Session: Myeloproliferative Neoplasms – Clinical.)
Ruxolitinib-Parsaclisib Combination Studies
Add-On Parsaclisib (a PI3kδ inhibitor) in Patients with Myelofibrosis and Suboptimal Response to Ruxolitinib: Interim Analysis from a Phase 2 Study (Abstract #EP1075. Session: Myeloproliferative Neoplasms – Clinical.)
Tafasitamab
Estimation of Long-Term Survival with Tafasitamab + Lenalidomide in Relapsed/Refractory Diffuse Large B-Cell Lymphoma3 (Abstract #EP553. Session: Aggressive Non-Hodgkin Lymphoma – Clinical.)
First-MIND: A Phase 1b, Open-Label, Randomized Study to Assess Safety of Tafasitamab or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed DLBCL3 (Abstract #EP496. Session: Aggressive Non-Hodgkin Lymphoma – Clinical.)
Lenalidomide-Induced Effects on Cell Surface Expression of CD19 and CD20 in DLBCL Cell Lines and Functional Impact on Antibody-Mediated Cytotoxicity3 (Abstract #EP879 . Session: Lymphoma Biology & Translational Research.)
In addition to the presentations noted above, more than 10 publications highlighting data from Incyte’s portfolio will be made available by EHA as publications. Notably, these publications include bioequivalence and bioavailability data for ruxolitinib’s once-daily extended release (XR) formulation – Bioequivalence of 50 mg Once-Daily Ruxolitinib Extended Release (XR) Tablets Compared to 25 mg Twice-Daily Ruxolitinib Immediate Release (IR) Tablets (Abstract #PB1706) and Relative Bioavailability and Dose Linearity of Five Strengths of Ruxolitinib Extended Release (XR) Tablets (Abstract #PB1717).
Full listings for oral presentations and ePoster sessions are available on the EHA website: https://library.ehaweb.org. Oral, poster discussion and poster sessions, as well as track-based clinical science symposia, accepted for presentation at EHA will be available on demand for registered attendees beginning Friday, June 11, 2021, through Sunday, August 15, 2021.
About Incyte
Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.
Forward-Looking Statements
Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the presentation of data from the Company’s or partner company’s ongoing clinical development pipeline, and whether or when any development compounds or combinations will be approved or commercially available for use in humans anywhere in the world outside of the already approved indications in specific regions, its presentation plans for the upcoming EHA meeting and its goal of improving the lives of patients, contain predictions, estimates and other forward-looking statements.
These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials and the ability to enroll subjects in accordance with planned schedules; the effects of the COVID-19 pandemic and measures to address the pandemic on the Company’s clinical trials, supply chain and other third-party providers, and development and discovery operations; determinations made by the FDA and other regulatory authorities outside of the United States; the Company’s dependence on its relationships with its collaboration partners; and other risks detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission, including its annual report for the year ended December 31, 2020, and the quarterly report on Form 10-Q for the quarter ended March 31, 2021. The Company disclaims any intent or obligation to update these forward-looking statements.
________________
1 Takeda-sponsored abstract.
2 Novartis-sponsored abstract.
3 MorphoSys-sponsored abstract.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210512006007/en/
Contact information
Media
Catalina Loveman
+1 302 498 6171
cloveman@incyte.com
Investors
Christine Chiou
+1 302 274 4773
cchiou@incyte.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enhertu ® Approved in the EU as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer27.10.2026 09:30:00 EET | Press release
Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. In DESTINY-Breast05, Enhertu significantly reduced the risk of in
Avanzanite Bioscience Expands UK Presence and Appoints Sarah O’Connell as Country Manager27.10.2026 09:00:00 EET | Press release
Avanzanite Bioscience B.V., a European pharmaceutical company focused on rare diseases, today announced the expansion of its United Kingdom (UK) presence and the appointment of Sarah O’Connell as UK Country Manager. The move strengthens Avanzanite’s long-term commitment to the UK and its ability to help eligible patients access innovative rare disease medicines. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261027035012/en/ Sarah O'Connell, Country Manager, UK, Avanzanite Bioscience “The UK is essential to our ambition of building Avanzanite into a European rare disease champion. We feel a deep and lasting connection to this market and there is no European reach without the UK,” said Adam Plich, co-founder and CEO, Avanzanite Bioscience. “At a time when parts of the life sciences sector are reassessing their investment and presence in the UK, we are choosing to commit and build for the long term. With Sarah’s extensive rare
LTM Secures Strategic Engagement with a Global Banking and Financial Services Firm27.10.2026 06:30:00 EET | Press release
LTM, the Business Creativity partner to the world's largest enterprises, has secured a strategic engagement with a large global banking and financial services firm, further strengthening its position as a trusted technology and transformation partner to leading financial institutions. This two-year engagement is already underway with an option to extend for an additional year and has a potential value of up to USD 100 million. The engagement reflects the continued expansion of LTM’s relationship with the client and its growing role in advancing strategic technology programmes and supporting supplier consolidation initiatives across the organization. Under the agreement, LTM will serve as a preferred partner driving the consolidation and delivery of strategic technology requirements across key wealth, personal banking, and global functions. The engagement will leverage LTM’s deep banking-domain expertise, engineering excellence, and global delivery capabilities to support the client’s t
DDN Selected to Modernize Research Data Infrastructure at UNSW Sydney26.10.2026 23:30:00 EET | Press release
DDN, the global leader in AI and data intelligence solutions, today announced that UNSW Sydney has selected DDN to deliver a new research data storage environment as part of the university’s Research Data Experience (RDE) program. Working with Australian software company Arcitecta, DDN will combine its EXAScaler parallel file system with Arcitecta’s Mediaflux® data management platform to help researchers spend less time managing data and more time using it. Following an extensive 18-month evaluation, UNSW selected an integrated approach that will replace 11 legacy storage systems with a coordinated environment for high-performance storage and enterprise data management. The decision reflects a broader challenge facing research-intensive institutions: how to support rapidly expanding scientific datasets while simplifying infrastructure, improving data accessibility and managing long-term costs. Built for data-intensive research, high-performance computing and AI workloads, DDN EXAScaler
Agent Assurance by TestMu AI Is Now Generally Available, Letting Teams Test What Their AI Agents Actually Change26.10.2026 17:15:00 EET | Press release
TestMu AI (formerly LambdaTest), the world's first Agentic AI-powered Quality Engineering platform, today announced the general availability of Agent Assurance. Agent Assurance tests AI agents that take actions, such as calling tools, writing files, and changing records, by checking what a run actually changed rather than what the agent says it did. Any team can now create a TestMu AI account and run it against its own agent without booking a demo first. Agent Assurance launched on August 17, 2026, behind a waitlist and a guided onboarding session. Since then, Rook, the CLI that runs Agent Assurance, has shipped a steady run of releases, shaped by feedback from early teams. Agent evaluation has mostly graded the final reply, and that reply can be wrong about the agent's own work. In CXBench, a benchmark of LLM agents in regulated customer-experience workflows published in October 2026, 80.1% of runs that reached the right outcome still failed the process checks, and only 13.8% passed b
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom